Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations

Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, according to an international Phase II trial led by The University of Texas MD Anderson Cancer Center.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/targeted-therapy-erdafitinib-effective-for-patients-with-advanced-bladder-cancer-and-specific-gene-mutations